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Over 90% of children with standard risk-acute lymphoblastic leukemia (SR-ALL) will 
survive, but there are limited data concerning their psychological adjustment during 
treatment. We prospectively assessed symptoms of anxiety, depression and behavioral 
disturbances in children with SR-ALL during the first 12 months of therapy and 
identified factors associated with psychological distress. We conducted a cohort study of 
159 children 2-9.99 years old with SR-ALL enrolled and treated on Children’s Oncology 
Group study AALL0331 at 31 selected sites. The primary caregiver completed the 
Behavior Assessment System for Children-Second Edition, the Family Assessment 
Device-General Functioning, and the Coping Health Inventory for Parents at about 1, 6 
and 12 months after starting treatment. The mean scores for anxiety, depression, 
aggression and hyperactivity in the child were within the average range at all timepoints. 
However, compared to a normative population, a higher percentage of children scored in 
the at-risk/clinical range for depression throughout the first year: one month (21.7% vs. 
15%, p=0.022), six months (28.6% vs. 15%, p<0.001), and twelve months (21.1% vs. 
15%, p=0.032). For anxiety, a greater percentage scored in the at-risk/clinical range at 
one month (25.2% vs. 15%, p=0.001), but then reverted to expected levels at six and 
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twelve months after diagnosis. Children with elevated anxiety symptoms at one month 
were more likely to have elevated symptoms at six (OR=7.70, p<0.001) and twelve 
months (OR=7.11, p=0.002) after diagnosis. Similarly, those with elevated depression 
symptoms at one month were more likely to have elevated symptoms at six (OR=3.51, 
p=0.015) and twelve months (OR=3.31, p=0.023) after diagnosis. In multivariate 
longitudinal analysis with repeated measures at the three timepoints, unhealthy family 
functioning was associated with anxiety (OR=2.24, p=0.033) and depression (OR=2.40, 
p=0.008). Hispanic ethnicity was also associated with anxiety (OR=3.35, p=0.009). 
Worse physical functioning (p=0.049), unmarried parents (p=0.017), and less reliance on 
the coping strategy of maintaining social support (p=0.004) were associated with 
depression. Based upon parental assessments, anxiety is a significant problem in young 
children with ALL one month after starting therapy, though it resolves within the first 
year. Depression remains a significant problem for at least one year, highlighting the 
need for psychosocial screening and the availability of mental health staff. We found that 
we could identify children at one month after diagnosis who were substantially more 
likely to have poor emotional functioning throughout the first year of therapy. Children of 
Hispanic ethnicity or from families reporting unhealthy family functioning may be 
particularly vulnerable.  
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INTRODUCTION 
Background and Significance  
Acute lymphoblastic leukemia (ALL) is the most common type of cancer in children, 
comprising 25% of malignancies diagnosed before age 15 years and 19% diagnosed 
before age 20 years (1). Its peak incidence is between 2 and 5 years old (2). Children can 
present, often insidiously, with various constellations of signs and symptoms. Bone 
marrow infiltration of leukemic cells can lead to signs of bone marrow failure, including 
fevers (neutropenia), fatigue (anemia), petechiae, and bleeding/bruising 
(thrombocytopenia). Extramedullary disease can present with lymphadenopathy and 
hepatosplenomegaly (2). A definitive diagnosis is established with a bone marrow 
examination. The leukemic cells represent a clonal expansion of cells that originated 
either from the B- or T-cell lineages. The most common immunophenotype is precursor 
B-cell ALL (3).  
 
In the 1960s, the five-year survival rate of childhood ALL was less than 10% (4). During 
subsequent decades, survival rates improved substantially. For United States patients, 
five-year survival increased to 77% in 1985-1994, to 87% in 1995-2000, and to over 90% 
in 2000-2005 (1). In particular, children diagnosed with standard-risk ALL and treated on 
a Children’s Oncology Group (COG) clinical trial between 2000 and 2005 had a 95% 
survival rate (1).  
 
The improved survival rate is, in part, due to more aggressive treatment protocols 
administered over 2½ to 3½ years (5). Contemporary ALL treatment regimens generally 
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consist of three main phases: induction of remission, consolidation/intensification with 
reinduction segments, and prolonged continuation/maintenance (6). In each phase, 
combination chemotherapy is delivered primarily in the outpatient setting. In addition, 
patients receive central nervous system prophylaxis with intrathecal medications. Some 
patients also receive cranial radiation. At diagnosis, patients are classified as standard-
risk or high-risk based on age and initial white blood cell count. National Cancer Institute 
criteria for standard-risk ALL include white blood cell count <50,000/microliter and age 
1.0-9.99 years (7). There are additional risk stratifications and specific protocols tailored 
to immunophenotype and risk status (6). 
 
Since the vast majority of children treated for ALL are expected to become long term 
survivors, more attention has been devoted to understanding patients’ quality of life. In 
1998, the American Cancer Society Task Force on Children and Cancer stated: “The 
progress achieved in attaining 80% survival among children and young adults with cancer 
can be justified only if their physical, emotional and social quality of life are also 
protected” (8). We know that the multiple different chemotherapeutic agents used to treat 
ALL have the potential to affect mood and behavior. In particular, corticosteroids, which 
are a key component of ALL therapy, affect mood, behavior, and cognition (9). In 
addition, the 2½ - 3½ years of frequent outpatient visits and unscheduled hospital 
admissions for complications can take an emotional toll on patients and families. 
Therefore, it is important to understand the psychological status of ALL patients and 
make sure their psychosocial needs are fulfilled.  
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Psychological Health of Childhood Cancer Survivors 
Information about the behavioral and emotional health of children with cancer is largely 
based on studies of children after therapy, rather than children on active treatment (10). In 
1981, Drs. Koocher and O’Malley published the results of their landmark study of the 
psychosocial consequences of surviving childhood cancer (11). The study, which began 
in 1975, was the first to assess a sizeable group of childhood cancer survivors and their 
families using standardized instruments in conjunction with clinical interviews. Of the 
117 survivors in their cohort, the majority were doing well, but approximately 25% were 
rated as having impaired psychological adjustment. The prognosis of childhood cancer 
has improved dramatically since Drs. Koocher and O’Malley’s work and a vast amount 
of literature regarding psychosocial adjustment of survivors has accumulated.  
 
A substantial portion of the literature regarding the psychological status of survivors 
reported data from the Childhood Cancer Survivor Study (CCSS). The CCSS is a 
retrospective cohort of over 14,000 childhood cancer survivors and their siblings from 26 
institutions in the United States who were diagnosed with cancer between 1970 and 1986 
(12). Taken together, results of the CCSS and other childhood cancer survivor studies 
indicate that most survivors have few emotional and behavioral problems; however, a 
subset of patients experience significant psychological distress (13, 14). For instance, in a 
study of 9,535 survivors and 2,916 siblings from the CCSS cohort, survivors were more 
likely than their siblings to report clinical levels of emotional distress (OR=2.2; 95% CI, 
1.8-2.8) and impairments in mental health (OR=1.8; 95% CI, 1.6-2.1) (15).  
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The data on leukemia patients has yielded similar results. In another CCSS analysis, the 
2,090 survivors of ALL reported more symptoms of anxiety (mean score: 47.62 vs. 
46.36, p<0.003) and global distress (mean score: 48.84 vs. 46.64, p<0.003) than their 
siblings (16). The effects sizes, however, were small and mean scores for both the 
survivor and sibling participants were below population norms. Likewise, a subset of 
1,345 adolescent survivors of leukemia in the CCSS cohort had higher rates of 
anxiety/depression (OR=1.6; 99% CI, 1.2-2.2) and antisocial behavior (OR=1.7; 99% CI, 
1.3-2.3) than their siblings (17). In trying to determine which subsets of patients are 
particularly vulnerable, a number of variables have been studied. Factors that have been 
associated with psychological distress in survivors include exposure to more intensive 
chemotherapy, poor physical health, female sex, unmarried status, and lower annual 
household income (14, 16, 17). In addition, there is evidence that emotional distress in 
survivors is related to engagement in risky health behaviors, such as smoking and heavy 
alcohol use (14, 18).    
 
Cross-Sectional Data on Children on Active Treatment for ALL 
Less research about psychosocial outcomes has focused on the active treatment period. 
Overall, the available literature indicates that children on treatment have poorer 
emotional and behavioral health compared with childhood cancer survivors (19). The 
data available on children undergoing treatment for ALL, however, has come from cross-
sectional studies that yielded mixed results (20-22). The largest study of this nature, by 
Sung and colleagues, evaluated 206 children ages 2-18 years with standard-risk and high-
risk ALL at five pediatric cancer centers in Canada (20). The patients were at various 
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points in therapy, but all had been diagnosed at least two months prior to enrollment in 
the study. On the Pediatric Quality of Life Inventory (PedsQL), the patients had median 
psychosocial summary and emotional functioning scores that were 1-2 standard 
deviations lower than healthy population norms. However, differences were not detected 
between participants in different phases of therapy. Children who were on phases 
preceding Maintenance had similar emotional (60.0 vs. 65.0, p=0.087) and psychosocial 
(66.7 vs. 58.3, p=0.152) summary scores to children on Maintenance. Similarly, in a 
study of 31 ALL patients on Maintenance therapy, Waters and colleagues found that ALL 
patients had significantly poorer behavioral and emotional health than a healthy 
population (22). On the Child Health Questionnaire (CHQ), the 5-17 year old patients 
had a mean emotional/behavioral health scale score of 80.90 compared to 93.73 in a 
representative, healthy population (p<0.001).  
 
In contrast, in a study by Shankar and colleagues, the 46 children on treatment for 
leukemia had similar psychological functioning to 481 healthy controls (21). This study 
of children 8-12 years old utilized the child self-report Minneapolis-Manchester Quality 
of Life-Youth Form (MMQL-YF). Mean psychological functioning scores were 3.93 and 
3.82 for the leukemia patients and controls, respectively (p=0.17). Since this data is all 
cross-sectional, the developmental trajectory of the psychosocial adjustment of ALL 
patients throughout therapy cannot be determined. Furthermore, it is not clear if the 
measurement of children at disparate times of treatment contributed to the inconsistencies 
among various study results. 
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Longitudinal Data on Children on Active Treatment for Cancer  
The few longitudinal studies of psychological adjustment in children on treatment for 
cancer were small and included diverse cancer populations (23). For example, Landolt 
and colleagues assessed a cohort of 52 patients in Switzerland at 6 weeks and 1 year after 
the diagnosis of leukemia, lymphoma, brain tumors or other solid tumors (24). On the 
TNO-AZL Questionnaire for Children’s Health-Related Quality of Life (TACQOL), the 
6.5-15 year old children reported significantly worse positive emotional functioning than 
the community sample at six weeks (mean scores: 5.9 vs. 7.2, p<0.001) after diagnosis. 
Mean scores improved from the first to second timepoint (5.9 vs. 6.6, p<0.05); however, 
at one year after diagnosis, mean scores were still significantly reduced compared to the 
community sample (6.6 vs. 7.2, p<0.01). The other measure of psychological functioning 
in this study, negative emotional functioning, was not increased in patients. Only 17 
patients in the sample had a diagnosis of leukemia. Therefore, it was difficult to ascertain 
if there were differences in leukemia patients’ emotional functioning compared to 
patients with other diagnoses.  
 
In a series of two longitudinal studies that yielded some dissimilar results to Landolt and 
colleagues’ study, Sawyer and colleagues evaluated a cohort of 39 patients immediately 
after diagnosis and then annually for the next four years (23, 25). Compared to a 
community sample of 49 children in South Australia, the patients, who were 2-12 years 
old at diagnosis, had worse psychological adjustment immediately after diagnosis. Mean 
scores on two scales of the Child Behavioral Checklist (CBCL) were increased in the 
patients (higher scores indicate more problems): Total Problems (54.5 vs. 51.0, p<0.05) 
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and Internalizing Problems (56.2 vs. 50.7, p=0.006).  Similarly to Landolt and 
colleagues’ study, patients’ scores on the Internalizing Problems scale improved across 
time (F(4,190) = 2.8, p = 0.03). Unlike the Landolt and colleagues study, however, by 
one year after the initial assessment, all CBCL scale scores were similar between the 
patient and community groups. The scores remained similar at all subsequent 
assessments. Externalizing Problems were not a significant issue at any timepoint. Again, 
Sawyer and colleagues’ study included children with Wilms Tumor, Hodgkin’s 
Lymphoma, and other cancers in addition to leukemia. While 56% of the sample had a 
diagnosis of ALL, data from the ALL population was not analyzed separately.  
 
Determinants of Psychological Health  
The literature has also been inconsistent regarding determinants of psychosocial 
functioning (19, 26). Many of the aforementioned studies indicate that there are 
vulnerable subgroups of children who experience greater psychological distress, but there 
is disagreement about which groups are vulnerable. In a systematic review of predictors 
of quality of life in children with cancer and childhood cancer survivors, Klassen and 
colleagues identified a large number of variables (19). Yet, most of the variables in the 58 
articles reviewed were examined in only a few studies. Furthermore, they were often 
significant in one study, but not replicated by the others. For example, lower 
socioeconomic status was associated with worse emotional functioning in a cross-
sectional study of 376 children on active treatment for cancer (OR=1.77; 95% CI, 1.00-
3.12) (27). Conversely, in another 6 studies that explored the relationship between 
socioeconomic status and quality of life, no association was found (19). The few factors 
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that were consistently related to quality of life included certain cancer variables (e.g., 
type of cancer), treatment variables (e.g. treatment intensity), and treatment-related (e.g. 
presence of late effects) variables.  
 
An inspection of more specific studies that included significant samples of children on 
treatment for ALL indicates that several child and family factors may also be associated 
with psychological functioning. Both younger and older age at diagnosis or assessment 
predicted worse emotional and behavioral functioning in different studies (20, 24, 28, 
29). For instance, in a cross-sectional study of 215 children (24.2% with leukemia) in 
Egypt, older age at assessment was related to better emotional functioning (β=0.15, 
p<0.01) (29). In contrast, Sung and colleagues’ study of 206 children with ALL 
(reviewed above) observed that older children had worse psychosocial summary scores 
on the PedsQL (β= -0.72, p=0.02) (20). There is also data showing an association 
between female gender and worse emotional health (20, 30). In a cohort study of 101 
children (33% with ALL) in Sweden, boys had higher mean “Emotions” scores than girls 
2.5 months (62.2 vs. 49.4, p<0.01) and 5 months (67.4 vs. 52.6, p<0.01) after the start of 
treatment (30).  
 
In addition to child factors, several family factors have been associated with worse 
psychosocial functioning in children, including parental health and well-being and 
unmarried parents. In a study of 87 families (63% with ALL), mothers who had worse 
scores on the maternal worry scale rated their child’s emotional functioning to be lower 
(r= -0.36, p<0.05) (31). Similar correlations were demonstrated in other studies that 
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measured different aspects of parental distress including anxiety and depression (32-34). 
Married parents were associated with better emotional functioning in Sung and 
colleagues’ report (β=9.66, p=0.009) (20). Again, most of this literature reviewed did not 
separately analyze ALL patients. Thus, it is unknown which variables are the most 
important determinants of psychological functioning in children with ALL.  
 
Role of Family Functioning and Coping Behaviors  
The contribution of family functioning and coping behaviors to children’s emotional 
functioning is of particular interest because there are emerging data that suggest these 
factors may be modifiable. Currently, there is compelling evidence for the efficacy of 
family interventions in non-cancer childhood illness populations, such as in Diabetes 
Mellitus (35). Armour and colleagues conducted a meta-analysis of eight randomized 
controlled trials that evaluated the effectiveness of family interventions in families of 
children with Type 1 diabetes (36). This meta-analysis revealed an overall decrease in 
Hemoglobin A1C (HbA1C) levels in children whose families were in the intervention 
versus control groups. The pooled effect size for HbA1C changes was -0.6% (95% CI, -
1.2, 0.1). In addition, five of the six studies analyzed demonstrated a significant 
improvement in family conflict. However, this could not be quantified in the meta-
analysis because of differences in family climate measures between studies (36). Similar 
published evidence is available for family interventions for children with obesity and 
cystic fibrosis (35, 37, 38).   
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The evidence for family interventions in pediatric cancer populations is less certain; 
however, data from a few small studies are supportive. For example, Kazak and 
colleagues found that a family-based intervention for adolescent survivors of childhood 
cancer and their families improved symptoms of posttraumatic stress (39). Kazak and 
colleagues conducted a randomized clinical trial of the Surviving Cancer Competently 
Intervention, a four-session, one-day whole family intervention that integrates cognitive-
behavioral treatment with family therapy. Of the 150 families who participated, the 
adolescent survivors in the intervention group improved more on symptoms of arousal 
than did those in the wait-list control group, t(20) = 3.13, p < .01. In addition, there was a 
greater reduction in symptoms of intrusion in the fathers in the intervention versus 
control group, t(116) = 3.08, p < .01 (39). Though several of posttraumatic stress and 
anxiety outcomes did not change with the intervention, Kazak and colleagues’ data 
supported the usefulness of brief family-based treatments in childhood cancer. 
 
Limitations of Previous Research and Their Implications for Future Research  
The extant literature on the psychological adjustment of children with cancer has been 
limited by small sample sizes, diverse patient populations, and cross-sectional designs. In 
addition, many of the studies reviewed above utilized instruments that may not be the 
most appropriate measures of psychological adjustment in childhood cancer populations. 
The use of the Child Behavioral Checklist (CBCL) in children with chronic illnesses, for 
example, has been cautioned against because of: (1) the confounding of somatization 
symptoms with the physical symptoms of illness/therapy; and (2) because of inadequate 
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sensitivity to detect subclinical levels of psychological problems (40). These study design 
limitations may, in part, account for the inconsistencies in outcomes of prior research.  
 
Two systematic reviews of quality of life in children with ALL are available (10, 26). 
Both concluded that there is a need for ongoing research that uses longitudinal designs 
and larger sample sizes to study childhood ALL patients’ quality of life. Yet, no study to 
date has assessed the prospective, longitudinal psychological functioning of children 
undergoing contemporary therapy for standard risk-ALL (20).  
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STATEMENT OF PURPOSE, HYPOTHESES, AND SPECIFIC AIMS 
We prospectively evaluated the emotional and behavioral functioning of a large, 
representative sample of children with acute lymphoblastic leukemia enrolled on a 
frontline Children’s Oncology Group (COG) therapeutic study during the first year of 
therapy. We sought to: 
(1) Describe the longitudinal trajectory of the psychological adjustment of 
children during their first year of therapy by measuring symptoms of anxiety, 
depression and behavioral disturbances at three select timepoints. 
(2) Identify factors associated with worse psychological functioning in children, 
including potentially modifiable variables related to family functioning and 
coping that could be targeted in future interventions.  
 
We hypothesized that:  
(1) Children with ALL would be at increased risk for poor psychological 
adjustment in the immediate post-diagnosis period. Psychosocial functioning 
would then improve; however, a subset of children would have persistently 
poor emotional and behavioral health throughout the first year of therapy.  
(2) Predictors of elevated symptoms of anxiety, depression and behavioral 
problems would include: older age at diagnosis, female gender, unhealthy 
family functioning, lack of family coping behaviors, and unmarried parents.   
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METHODS 
Study Population 
We conducted a prospective, longitudinal study of emotional and behavioral outcomes in 
children with standard risk acute lymphoblastic leukemia (SR-ALL) who were enrolled 
on COG protocol AALL0331 between April 2005 and March 2009 at 31 selected sites. 
For the AALL0331 therapeutic study, the population of patients with National Cancer 
Institute standard risk features by age (1.0-9.99 years) and white count (initial white 
blood cell count <50,000/microliter) were further risk stratified into standard risk-low, 
standard risk-average, and standard risk-high groups as detailed at trials.gov AALL0331 
(7, 41). For this study of emotional and behavioral outcomes, we included children in the 
standard risk-average group, who generally met the following additional criteria: 1) No 
central nervous system disease (white blood cells in cerebrospinal fluid <5/microliter); 2) 
No testicular leukemia (no testiculomegaly); 3) A rapid early response to therapy based 
on bone marrow morphology at day 8/15 of induction therapy and bone marrow minimal 
residual disease burden at the end of induction; and 4) No unfavorable cytogenetic 
features (e.g. no triple trisomies or TEL-AML1) (42).  
 
Additional eligibility requirements included age ≥ 2 years and at least one parent with 
reading comprehension of English or Spanish, the languages for which validated surveys 
exist. The sites that participated in this study were chosen from all COG sites to include a 
combination of community-based and tertiary care centers with available staffing to 
administer the additional surveys for this ancillary study. Participating sites are listed in 
Table 1. 
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Table 1. List of participating institutions 
 
Children’s Hospital Medical Center, Akron, OH 
Children’s Hospital at the Cleveland Clinic, Cleveland, OH 
Children’s Hospital Colorado, Aurora, CO 
Children’s Hospital of Central California, Madera, CA 
Children’s Hospital and Clinics of Minnesota, Minneapolis and St. Paul, MN 
Children’s Hospital, New Orleans, LA 
Children’s Hospital of Pittsburgh, Pittsburgh, PA 
Seattle Children’s Hospital, Seattle, WA 
Helen DeVos Children’s Hospital, Grand Rapids, MI 
Doernbecher Children’s Hospital, Portland, OR 
Nemours/Alfred I. duPont Hospital for Children, Wilmington, DE 
East Tennessee Children’s Hospital, Knoxville, TN 
Hackensack University Medical Center, Hackensack, NJ 
Randall Children’s Hospital at Legacy Emanuel, Portland, OR 
Loma Linda University Medical Center, Loma Linda, CA 
Midwest Children’s Cancer Center, Milwaukee, WI 
Nevada Cancer Research Foundation 
Princess Margaret Hospital for Children, Perth, Australia 
St. Vincent Hospital, Regional Cancer Center, Green Bay, WI 
Packard Children’s Hospital at Stanford, Stanford, CA 
SUNY Upstate Medical University, Syracuse, NY 
St. Joseph’s Children’s Hospital of Tampa, Tampa, FL 
University of Alabama at Birmingham Hospital, Birmingham, Al 
University of Florida Academic Health Center, Gainesville, FL 
University of Minnesota Medical Center, Fairview, Minneapolis, MN 
Children’s Hospital, University of Mississippi Medical Center, Jackson, Mississippi 
University of New Mexico Children’s Hospital, Albuquerque, New Mexico 
University of Texas Southwestern Medical Center, Dallas, TX 
American Family Children’s Hospital, University of Wisconsin Children’s Hospital, Madison, WI 
Children’s Hospital at Vanderbilt, Nashville, TN 
 
 
The treatment phases in the AALL0331 protocol included Induction (35 days), 
Consolidation (29-57 days), Interim Maintenance (57 days), Delayed Intensification (57 
days), and Maintenance (2-3 years). Patients received a three-drug, four-week induction 
with vincristine, PEG-asparaginase, dexamethasone (6 mg/m2/day x 28 days) and 
intrathecal chemotherapy. No patients received cranial radiation. There were two 
therapeutic randomizations: (1) a standard Consolidation phase vs. an intensified 
Consolidation phase and (2) standard Interim Maintenance and Delayed Intensification 
phases vs. augmented Interim Maintenance and Delayed Intensification phases. In 2008, 
the second randomization was halted based upon the results of the CCG 1991 SR-ALL 
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trial (5). Detecting differences in emotional and behavioral functioning between the four 
treatment groups was not an objective of the current study. However, we were able to 
analyze if there was an effect of treatment group on psychosocial functioning.  
 
One hundred ninety four patients who were enrolled in AALL0331 at the participating 
sites met the eligibility criteria for this ancillary study. Of these, 24 declined and 170 
consented to participate. Of those who consented, 4 withdrew from AALL0331 before 
the first required survey evaluations and 7 were not given the evaluations because of error 
at the study sites (Figure 1). The 159 participants (82% of eligible) were similar to the 35 
eligible nonparticipants in terms of age at diagnosis and gender, but there were some 
differences in ethnicity (Table 2).  
 
Figure 1. Participant flowchart 
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Table 2. Comparison of participants to eligible nonparticipants 
 Participants, 
(n = 159) 
Eligible 
nonparticipants, 
(n = 35) 
P-value 
Age group at diagnosis, no. (%) 
  Pre-school (ages 2-4) 
  School-age (ages 5-9) 
 
86 (54.1%) 
73 (45.9%) 
 
24 (68.6%) 
11 (31.4%) 
 
0.134 
 
Sex, no. (%) 
  Female 
  Male 
 
76 (47.8%) 
83 (52.2%) 
 
19 (54.3%) 
16 (45.7%) 
 
0.576 
Child ethnicity, no. (%) 
  White, non-Hispanic 
  Black, non-Hispanic 
  Hispanic 
  Other 
 
108 (67.9%) 
11 (6.9%) 
26 (16.4%) 
14 (8.8%) 
 
16 (45.7%) 
1 (2.9%) 
9 (25.7%) 
9 (25.7%) 
 
0.011 
Marital status of parents, no. (%) 
  Married  
  Not Married  
  Missing 
 
105 (66.0%) 
45 (28.3%) 
9 (5.7%) 
  
 
Maternal highest level of 
education, no. (%) 
  Less than college  
  At least some college  
  Missing 
 
 
92 (57.9%) 
55 (34.6%) 
9 (5.7%) 
  
 
Family Income, no. (%) 
  Less than $50,000 
  $50,000-$79,999 
  $80,000 or more 
  Missing 
 
72 (45.3%) 
25 (15.7%) 
30 (18.9%) 
32 (20.1%) 
  
 
Therapeutic randomization, no. 
(%) 
  Standard CS/standard IM-DI1 
  Intensified CS/standard IM-DI1 
  Standard CS/augmented IM-DI1 
  Intensified CS/augmented IM-DI1 
 
 
42 (26.42%) 
51 (32.08%) 
37 (23.27%) 
29 (18.24%) 
  
1CS = consolidation, IM = Interim Maintenance, DI= Delayed Intensification 
 
Procedures 
The institutional review board of each participating center as well as the Yale University 
Human Investigation Committee approved the current study. Eligible patients were asked 
to participate at the end of Induction and were approached for consent at the same time 
that they were approached for consent to the post-Induction portion of the therapeutic 
study. Informed consent and assent, when indicated, was obtained for all participants.  
 
!!
23!
The identified primary caregiver (the child’s mother in 84% of instances), who 
accompanied the child to clinic visits, completed surveys at three selected timepoints 
during their child's first year of therapy: day 1 of Consolidation (approximately 1 month 
after diagnosis), the end of Delayed Intensification (approximately 6 months after 
diagnosis), and six months after starting Maintenance (approximately 12 months after 
diagnosis). The timepoints were chosen to reflect the children’s experiences at different 
phases of therapy. The first represented the induction experience, the second represented 
the delayed intensification experience, and the third reflected the children’s psychosocial 
functioning mid-Maintenance. Of the 159 participants, 145 completed the evaluations at 
the first timepoint, 131 completed the evaluations at the second timepoint, and 136 
completed the evaluations at the third timepoint.   
 
Measures 
Emotional and behavioral functioning was assessed by the Behavioral Assessment 
System for Children, Second Edition: Parent Report Scale (BASC-2 PRS), a valid and 
reliable instrument that has been used successfully in pediatric oncology populations (40, 
43). The BASC-2 PRS, which has separate forms for parents of pre-school (ages 2-5 
years) and school-age (ages 6-11 years) children, contains 134-160 items. The instrument 
takes 10-20 minutes to complete and there are both English and Spanish versions. Parents 
rate the frequency of their child’s behavior on a 4-point Likert scale ranging from “never” 
to “almost always.” Example items include: “cries easily, listens to directions, gets very 
upset when things are lost, and acts out of control.” The BASC-2 PRS yields 
standardized T-scores ranging from 0-100 on a variety of clinical scales. T-scores from 
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60 through 69 represent the at-risk range and scores of 70 and above represent the 
clinical significant range. The BASC-2 PRS has been standardized on normative data 
obtained from a random sample of 12,350 children who are representative of the United 
States population based on gender, ethnicity, socioeconomic status, geographic region 
and culture (44). Expected frequencies of scores in the at-risk and clinically significant 
ranges in the normative (i.e. healthy comparison) population of children are available in 
the BASC manual (43). For the current study, the hyperactivity, aggression, anxiety and 
depression scales were selected because these are the problems known to be associated 
with steroids and observed in ALL patients. In addition, we did not include the 
somatization scale because the items are confounded by physical toxicities of therapy. 
Since the somatization scale is part of the internalizing problems composite scale, we also 
did not analyze the composite scale. 
 
Family functioning was evaluated using the General Functioning Scale of the Family 
Assessment Device (FAD-GF), which is appropriate for use in families experiencing 
chronic illnesses (45, 46). In this 12-item questionnaire, parents use a 4-point Likert scale 
ranging from “strongly disagree” to “strongly agree” to indicate the degree to which they 
feel each statement describes their family. Example items include “we are able to make 
decisions about how to solve problems,” “we cannot talk to each other about the sadness 
we feel,” and “we feel accepted for what we are.”  The possible scores range from 1-4, 
with higher scores reflecting greater perceived family dysfunction. A cut-off point for the 
FAD-GF has also been established; scores <2 signify healthy family functioning and 
scores ≥ 2 signify unhealthy family functioning (46).  
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Family coping was assessed using the Coping Health Inventory for Parents (CHIP), 
which has been validated for children with a variety of chronic illnesses (47). In this 45-
item checklist, parents rate how useful a specific coping behavior is on a 4-point Likert 
scale ranging from “not helpful” to “extremely helpful.” The CHIP has three subscales 
developed through factor analysis: (1) Maintaining Family Integration and Optimism 
(e.g. “Doing things together as a family,” 19 items, maximum score: 57); (2) 
Maintaining Social support and Self-Esteem (e.g. “Explaining our family situation to 
friends and neighbors so they will understand,” 18 items, maximum score: 54); and (3) 
Understanding the Medical Situation (e.g. “Reading about how other persons in my 
situation handle things,” 8 items, maximum score = 24). The coping patterns have α-
reliabilities of .79, .79, and .71, respectively (48). A higher score on each of the three 
subscales denotes a greater reliance on that particular coping pattern, but there are no 
normative scores. 
 
Physical functioning was measured with the “pain and hurt” and “nausea” subscales of 
the Pediatric Quality of Life Inventory (PedsQL) 3.0 Cancer Module. The PedsQL 
Cancer Module is a reliable and valid cancer-specific instrument (49). Parents rate how 
much of a problem each symptom has been during the past month on a 5-point Likert 
scale ranging from “never a problem” to “almost always a problem.” The “pain and hurt” 
(e.g. “aches in joints and/or muscles”) and “nausea” (e.g. “feeling too nauseous to eat”) 
subscales contain two and five items, respectively. Scores are reverse-scored and 
transformed on a 0-100 scale, with higher scores signifying better physical functioning.  
!!
26!
 
Socioeconomic data were obtained at the first timepoint from a parent demographic 
survey, which included questions about ethnicity, household income, marital status, 
maternal education and family size.   
 
Data Analysis  
Patient characteristics, including age at diagnosis, gender, and ethnicity, were 
summarized and compared between participants and eligible nonparticipants using an 
exact chi-square test to evaluate the potential for response bias.  
 
The primary outcomes of interest were the BASC-2 subscales for anxiety and depression. 
A patient was considered in the at-risk/clinically significant range if the corresponding 
subscale score was ≥ 60 and in the clinically significant if the score was ≥ 70, consistent 
with how this instrument was validated. The proportions of patients in the at-
risk/clinically significant and clinically significant ranges were compared to the 
corresponding proportions in the normative population, a comparison group of healthy 
children, using a one-sided binomial exact test.  
 
Both univariate and multivariate analyses were conducted to study the unadjusted and 
adjusted associations, respectively, of the patient characteristics with the two outcomes. 
For univariate analysis, a logistic regression model was tested with the dichotomized 
BASC-2 PRS scores for anxiety and depression (i.e. elevated scores, defined as subscale 
scores ≥ 60 vs. not-elevated scores, defined as subscale scores <60) as dependent 
!!
27!
variables, taking into consideration the dependence of repeated measurements at three 
timepoints for each participant. The following independent variables were considered in 
the model: age at diagnosis, gender, race/ethnicity, annual family income, maternal 
education, marital status of parents, therapeutic randomization, pain and hurt by parental 
report, nausea by parental report, as well as repeated measures of general family 
functioning and parental coping behaviors.  
 
Similar logistic regression model was used for conducting the multivariate analysis. For 
the multivariate analysis, the patient and family factors that were associated with elevated 
anxiety and depression scores by univariate analysis at p<0.1 were tested as the 
independent variables in the multivariate regression modeling. All of the analyses were 
performed using SAS software, version 9.2. 
 
Contributions to Methods  
Patients were enrolled in the study by clinical research associates at each of the 31 
participating sites in the United States and Australia. Research assistants at the sites also 
administered the surveys to families at each timepoint. The data was then sent to Yale. I 
created the databases and with the assistance of a more junior medical student, entered all 
the data. Beginning in 2011, I was also in charge of handling communication with the 
sites, which included tracking down missing data, reminding research assistants when 
timepoints were due, and sending necessary study materials to the sites. I developed the 
statistical plan with my mentor, but worked with a Children’s Oncology Group (COG) 
statistician at the Statistical Center in Gainesville, Florida to do the data analysis.  
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I prepared an abstract with this data that was accepted for poster presentation at the 
American Society of Pediatric Hematology/Oncology annual meeting in New Orleans, 
LA in May 2012. In addition, I wrote the manuscript of this study with critical feedback 
from my mentor, Dr. Nina Kadan-Lottick, as well as our co-authors from the Children’s 
Oncology Group. This manuscript is currently submitted to the Journal of Clinical 
Oncology.  
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RESULTS 
Participants 
The participants were a mean age of 4.9±2.2 years at diagnosis; 47.8% were female, 
16.4% were of Hispanic ethnicity, 66.0% had married parents, and 45.3% had annual 
family incomes of less than $50,000 (Table 2).  
 
Frequency of Emotional Problems 
Mean scores for anxiety and depression were stable and in the average range at all three 
timepoints. Mean anxiety scores were 53.2±12.7, 52.3±12.7, and 50.0±11.8 and 
depression scores were 52.1±11.1, 53.1±10.2, and 52.9±10.9 at one, six, and twelve 
months after diagnosis, respectively.  
 
However, the frequency of elevated anxiety and depression scores was greater than 
expected in a normative population of children (Figure 2). Beginning at one month after 
diagnosis, a greater percentage of children scored in the at-risk or clinically significant 
range for anxiety (25.2% vs. 15%, p=0.001) than the normative population, but then 
reverted to expected levels at six (17.5% vs. 15%, p=0.253) and twelve months (14.2% 
vs. 15%, p=0.542) after diagnosis. The frequency of anxiety scores that were elevated to 
the clinically significant range was greater than expected at one month (10.4% vs. 4%, 
p=0.001) and six months (8.7% vs. 4%, p=0.013) after diagnosis, but then declined to 
expected levels by twelve months after diagnosis (4.5% vs. 4%, p=0.448).  
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For depression, a higher percentage of children had scores in the at-risk or clinically 
significant range than expected throughout the first year of therapy: one month (21.7% 
vs. 15%, p=0.022), six months (28.6% vs. 15%, p<0.001), and twelve months (21.1 % vs. 
15%, p=0.038). However, the frequency of depression scores in the clinically significant 
range was not significantly different from expected levels at any timepoint: one month 
(5% vs. 4%, p=0.316), six months (6.4% vs. 4%, p=0.133), and twelve months (6.8% vs. 
4%, p=0.087). 
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Figure 2. Rates of elevated anxiety and depression scores in the first year after diagnosis of ALL 
 
 
 
 
Frequency of Behavioral Problems 
Mean scores for hyperactivity and aggression were also stable and in the average range at 
all three timepoints. Mean hyperactivity scores were 47.4±7.3, 49.2±8.2, and 50.0±8.5 
and aggression scores were 47.8±9.1, 48.9±9.2, and 49.6±9.1 at one, six, and twelve 
months after diagnosis, respectively.  
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Unlike anxiety and depression, the frequency of elevated hyperactivity and aggression 
scores was similar to that expected in a normative population. For hyperactivity, the 
percentage of children with scores in the at-risk or clinically significant range was 5.8 
(95% CI, 1.9-9.7), 11.8 (95% CI, 6.2-17.4), and 8.2 (95% CI, 3.6-12.9) at one, six, and 
twelve months after diagnosis, respectively. This is compared to 15% expected in a 
normative population. Zero, 1.6 (95% CI, 0-3.7) and 3.7 (95% CI, 0.5-6.9) percent had 
hyperactivity scores in the clinically significant range at the three timepoints, versus 4% 
in the normative population. Similarly, for aggression, the percentage of children with 
scores in the at-risk or clinically significant range was 5.9 (95% CI, 1.9-9.8), 6.6 (95% 
CI, 2.7-11.0), and 9.2 (95% CI, 4.3-14.2) at one, six, and twelve months after diagnosis, 
respectively. This is compared to 13% expected in a normative population. 2.9 (95% CI, 
0.1-5.6), 3.9 (95% CI, 0.5-7.3), and 3.0 (95% CI, 0.1-5.9) percent had aggression scores 
in the clinically significant range at the three timepoints, versus 4% in the normative 
population.  
 
Since hyperactivity and aggression were not found to be significant problems, they were 
not included in the longitudinal, univariate or multivariate analyses. 
 
Longitudinal Analysis 
Compared to children with non-elevated anxiety scores, those with anxiety scores in the 
at-risk/clinically significant range at one month after diagnosis were 7.70 (95% CI, 2.39-
24.85; p<0.001) times as likely to have elevated scores at six months and 7.11 times 
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(95% CI, 2.08-24.30; p=0.002) as likely to have elevated scores at twelve months after 
diagnosis. Children with elevated scores six months after diagnosis were 20.64 (95% CI, 
6.02-70.74; p<0.001) times as likely to have elevated scores twelve months after 
diagnosis. 
 
Compared to children with non-elevated depression scores, those with depression scores 
in the at-risk/clinically significant range at one month after diagnosis were 3.51 (95% CI, 
1.33-9.26; p=0.015) times as likely to have elevated scores at six months and 3.31 (95% 
CI, 1.20-9.10; p=0.023) times as likely to have elevated scores at twelve months after 
diagnosis. Children with elevated scores six months after diagnosis were 5.11 (95% CI, 
1.94-13.48; p<0.001) times as likely to have elevated scores twelve months after 
diagnosis (data not displayed) 
 
Predictors of Anxiety and Depression by Univariate Analysis  
Table 3 displays the results of the univariate analysis adjusted for time elapsed since 
diagnosis. The outcomes, anxiety and depression, were used as dichotomous variables 
(elevated vs. non-elevated scores). The independent variables were also transformed into 
dichotomous or categorical variables with several exceptions. The CHIP subscales, the 
“pain and hurt” scale, and the “nausea” scale are only valid as continuous variables. 
Therefore, they were inputted into the model as continuous variables. In this univariate 
analysis, significant predictors of anxiety and depressive symptoms included unhealthy 
family functioning and less reliance of each of the three coping patterns measured by the 
CHIP subscales. Hispanic ethnicity was significantly associated with worse anxiety 
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symptoms, but not depressive symptoms. Conversely, worse physical functioning as 
measured by the pain and hurt subscale of the PedsQL was significantly associated with 
depression, but not anxiety. There were no differences detected among the four treatment 
groups. 
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Table 3. Univariate association of patient and family factors with anxiety and depression 
 Anxiety Depression 
OR (95% CI) P OR (95% CI) P 
Age group at diagnosis 
Pre-school (ages 2-4) 
School-age (ages 5-12) 
 
Reference group 
0.62 (0.37,1.05) 
 
 
0.076 
 
Reference group 
0.78 (0.49,1.26) 
 
 
0.314 
Gender 
Male 
Female 
 
Reference group 
1.62 (0.97,2.72) 
 
 
0.067 
 
Reference group 
1.27 (0.79,2.02) 
 
 
0.325 
Race/Ethnicity 
White, non-Hispanic 
Hispanic 
Black, non-Hispanic 
Other 
 
Reference group 
3.32 (1.80,6.15) 
0.83 (0.23,2.96) 
1.61 (0.68,3.83) 
 
 
0.000 
0.769 
0.277 
 
Reference group 
1.36 (0.73,2.53) 
1.22 (0.46,3.25) 
1.59 (0.75,3.37) 
 
 
0.335 
0.696 
0.226 
Annual family income 
≥$50,000 
<$50,000 
 
Reference group 
1.11 (0.63,1.98) 
 
 
0.720 
 
Reference group 
1.17 (0.68,2.01) 
 
 
0.564 
Maternal education 
At least some college 
Less than college 
 
Reference group 
1.15 (0.64,2.04) 
 
 
0.642 
 
Reference group 
1.24 (0.74,2.09) 
 
 
0.410 
Marital status of parents 
Married 
Not married 
 
Reference group 
1.30 (0.74,2.29) 
 
 
0.354 
 
Reference group 
1.65 (0.99,2.75) 
 
 
0.054 
General Family 
Functioning1 
Healthy family 
functioning  
Unhealthy family 
functioning 
 
 
Reference group 
 
3.01 (1.76,5.15) 
 
 
 
 
 
<0.001 
 
 
Reference group 
 
2.37 (1.45,3.85) 
 
 
 
 
0.001 
Maintaining family 
integration coping 
behaviors2  
0.97 (0.94,0.99) 0.009 0.96 (0.94,0.98) 0.001 
Maintaining social 
support coping 
behaviors3  
0.96 (0.94,0.99) 0.005 0.95 (0.93,0.97) <0.001 
Understanding the 
medical situation coping 
behaviors4 
0.95 (0.90,1.00) 0.038 0.93 (0.89,0.98) 0.003 
Pain and hurt by parental 
report5  
0.99 (0.98,1.00) 0.062 0.99 (0.98,1.00) 0.016 
Nausea by parental 
report6 
0.99 (0.97,1.01) 0.186 0.99 (0.98,1.01) 0.230 
Therapeutic 
randomization7 
   SC/SIM-SDI 
   IC/SIM-SDI 
   SC/AIM-ADI 
   IC/AIM-ADI 
 
 
Reference group 
1.20 (0.60,2.40) 
1.23 (0.59,2.57) 
1.02 (0.45,2.28) 
 
 
 
0.598 
0.585 
0.970 
 
 
Reference group 
0.95 (0.50,1.78) 
1.00 (0.51,1.95) 
1.14 (0.56,2.33) 
 
 
 
0.862 
0.991 
0.713 
1Measured by the FAD-GF. 2Measured by the CHIP subscale 1. 3Measured by the CHIP subscale 2. 
4Measured by the CHIP subscale 5Measured by the PedsQL pain and hurt scale 6Measured by the PedsQL 
nausea scale 7SC = Standard Consolidation, IC = Intensified Consolidation, SIM-SDI = Standard Interim 
Maintenance and Standard Delayed Intensification, AIM-ADI = Augmented Interim Maintenance and 
Augmented Delayed Intensification 
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Predictors of Anxiety and Depression by Multivariate Analysis  
Table 4 displays the results of a multivariate model, which included the patient and 
family factors that were at least marginally significant (p≤0.1) by univariate analysis: age, 
gender, marital status, race/ethnicity, the pain and hurt subscale, general family 
functioning, and the three CHIP subscales. In this adjusted analysis, Hispanic ethnicity 
(OR=3.35; 95% CI, 1.36-8.24) and unhealthy family functioning (OR=2.24; 95% CI, 
1.07-4.70) remained significant predictors of worse anxiety symptoms. 
 
The significant predictors of worse depressive symptoms by adjusted analysis were 
unhealthy family functioning (OR= 2.40; 95% CI, 1.26-4.56), unmarried parents 
(OR=2.36; 95% CI, 1.17-4.75), worse physical functioning (p=0.049), and less reliance 
on maintaining social support coping behaviors (p=0.004).  
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Table 4. Multivariate analysis of the association of patient and family factors with anxiety and 
depression 
 
 Anxiety Depression 
OR (95% CI) P OR (95% CI) P 
Age group at diagnosis 
Pre-school (ages 2-4) 
School-age (ages 5-12) 
 
Reference group 
0.49 (0.24,1.01) 
 
 
0.053 
 
Reference group 
0.77 (0.42,1.40) 
 
 
0.387 
Gender 
Male 
Female 
 
Reference group 
1.57 (0.79,3.16) 
 
 
0.206 
 
Reference group 
1.24 (0.68,2.25) 
 
 
0.478 
Race/Ethnicity 
White, non-Hispanic 
Hispanic 
Black, non-Hispanic 
Other 
 
Reference group 
3.35 (1.36,8.24) 
0.85 (0.16,4.54) 
1.39 (0.42,4.52) 
 
 
0.009 
0.846 
0.592 
 
Reference group 
0.52 (0.20,1.39) 
0.86 (0.25,2.99) 
1.10 (0.42,2.87) 
 
 
0.192 
0.815 
0.849 
Marital status of parents 
Married 
Not married 
 
Reference group 
1.15 (0.49,2.56) 
 
 
0.797 
 
Reference group 
2.36 (1.17,4.75) 
 
 
0.017 
General Family 
Functioning1 
Healthy family 
functioning  
Unhealthy family 
functioning 
 
 
Reference group 
 
2.24 (1.07,4.70) 
 
 
 
 
 
0.033 
 
 
Reference group 
 
2.40 (1.26,4.56) 
 
 
 
 
0.008 
Maintaining family 
integration coping 
behaviors2  
0.99 (0.94,1.05) 0.771 1.04 (0.99,1.10) 0.085 
Maintaining social 
support coping 
behaviors3 
0.98 (0.94,1.03) 0.366 0.94 (0.91,0.98) 0.004 
Understanding the 
medical situation coping 
behaviors4  
1.00 (0.90,1.10) 0.964 0.95 (0.88,1.04) 0.283 
Pain and hurt by parental 
report5  
0.99 (0.98,1.00) 0.152 0.99 (0.98,1) 0.049 
1Measured by the FAD-GF. 2Measured by the CHIP subscale 1. 3Measured by the CHIP subscale 2. 
4Measured by the CHIP subscale 5Measured by the PedsQL pain and hurt scale   
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DISCUSSION 
Summary of Findings 
This is the first prospective, longitudinal study of emotional and behavioral functioning 
in a large sample of children with acute lymphoblastic leukemia to our knowledge. We 
found that depressive symptoms were a significant problem when first measured at the 
end of the first month of therapy, and remained at greater than expected levels at 6 and 12 
months after starting treatment. We found that anxiety was a significant problem at the 
end of the first month of therapy, but then its prevalence declined to levels expected in a 
normative population at 6 and 12 months after starting treatment. In addition, we found 
that children with elevated anxiety and depression symptoms at one month after diagnosis 
were significantly more likely to continue to have elevated symptoms throughout the first 
year of therapy. In adjusted analysis, we found that the strongest predictors of emotional 
functioning were family functioning and self-reported Hispanic ethnicity. Children whose 
parents reported unhealthy family functioning were 2.24 times at likely to have anxiety 
symptoms and 2.40 times as likely to have depressive symptoms. Hispanic children were 
3.35 times as likely as white, non-Hispanic children to have anxiety symptoms, but were 
not at increased risk for depressive symptoms. We did not find that age, gender, or family 
socioeconomic status predicted emotional functioning. In addition, we did not find 
behavioral changes to be a significant problem.  
 
Strengths of Current Study 
Our study is unique in that all participants had the same diagnosis with a high-expected 
cure rate, and were enrolled on a randomized clinical trial. Thus, unlike previous studies 
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that used heterogeneous populations, we were able to account for any differences due to 
therapeutic randomization. In addition, since we enrolled patients at 31 sites that 
represented a range of community and tertiary-care centers and rural and urban regions, 
our study can be generalized more than single institution studies. Furthermore, we had a 
high participation rate (82% of eligible), which greatly reduced but did not eliminate the 
potential for selection bias.    
 
Comparison of Results to Existing Longitudinal Data 
Limited published data are available regarding the longitudinal psychosocial functioning 
of children currently receiving chemotherapy. Our results can be most closely compared 
with the prospective, cohort study of 38 patients by Sawyer et al in South Australia (23, 
25). Consistent with our study, Sawyer et al found that children experience considerable 
emotional distress in the immediate post-diagnosis period. However, unlike our finding 
that depression was present at levels higher than expected throughout the first year, 
Sawyer et al found that by one year after diagnosis, children treated for cancer had 
similar psychological functioning as children in the community. The Sawyer et al study 
had limitations that our study overcame including: a small, heterogeneous sample and 
utilization of an instrument that was confounded by physical symptoms and did not 
distinguish between anxiety and depression symptoms.    
 
Evaluation of Family Functioning Findings 
To the best of our knowledge, this is the first study that reported family functioning as a 
predictor of emotional functioning of children with cancer. Previous research on family 
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functioning has focused on it as an outcome variable. There is one study that examined 
the role of family functioning on quality of life in children who recently completed 
chemotherapy, but it found both positive and negative correlations depending on the age 
group of the child (32). In other populations such as pediatric asthma patients, family 
dysfunction has been associated with children’s mental health (50). Our study used the 
General Functioning Scale of the Family Assessment Device, which measures perceived 
family cohesion and ability of family members to communicate with each other. Our 
results suggest that families who demonstrate worse cohesion and communication should 
be considered higher-risk and be offered more psychosocial support. There are 
psychosocial risk screening measures that have been developed, such as the validated and 
widely published Psychosocial Assessment Tool (PAT2.0), which can integrate 
assessments of family functioning (51). Furthermore, as previously discussed, family 
functioning may be a modifiable variable, and thus, our results support using or 
developing family-based interventions that target family functioning. 
 
Although anxiety and depressive symptoms may lessen throughout therapy, it is 
important to recognize the distress they cause and provide appropriate psychosocial 
interventions. The NIH consensus statement on cancer symptoms states: “All patients 
with cancer should have optimal symptom [includes pain, depression, and fatigue] 
control from diagnosis throughout the course of illness, irrespective of personal and 
cultural characteristics” (52). A wealth of psychosocial interventions exists for children 
with cancer, which include using cognitive-behavioral therapy, social-recreational 
activities, and psychoeducational interventions (53). Many interventions use family-based 
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methods, which have been associated with beneficial outcomes for children (54). 
Understanding the efficacy of various interventions is an ongoing area of research (53).  
 
Evaluation of Ethnicity Findings 
The significant association of Hispanic ethnicity with anxiety is novel in children with 
ALL. There is a single report that showed poorer emotional functioning in Hispanic 
children with cancer, but it only addressed the off-treatment period (55). We do know, 
however, that there are other differences between Hispanic and non-Hispanic children 
with ALL, including inferior survival rates in Hispanic children (1, 56). We do not have 
the data available to explain how Hispanic ethnicity leads to worse psychological 
functioning, but given these differences, this area of study deserves further attention.  
 
Limitations 
The current study has some methodological characteristics that should be considered in 
interpreting the results. First, some patients enrolled in the study did not complete the 
evaluations at all the required timepoints. This was due to a combination of withdrawals 
from the therapeutic study, administrative errors at study sites, and incomplete forms. We 
also used parent-report measures instead of child self-report because the majority of 
children in our study were too young to complete a validated self-report evaluation. In 
addition, we were able to associate family functioning with emotional functioning, but we 
were not able to determine the direction of the association from our data. It may be that 
children with better emotional functioning lessen the burden on their families.  
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Conclusions and Implications 
From this large, multisite, cohort study of children treated for SR-ALL, we conclude that 
symptoms of depression and anxiety are a significant problem in the immediate post-
diagnosis period. While anxiety symptoms lessen after the first month of therapy, 
depressive symptoms persist throughout at least the first year. We also found that we can 
identify children at one month after diagnosis who are substantially more likely to have 
worse psychological functioning as manifested by anxiety and depression throughout the 
first year of therapy. These findings provide for a compelling rationale to screen children 
with SR-ALL for psychological problems soon after diagnosis and to develop early 
interventions to target anxiety and depressive symptoms. Furthermore, our results 
highlight high-risk groups who should receive additional psychosocial support. We also 
found that unhealthy family functioning is significantly associated with anxiety and 
depression. Therefore, more studies elucidating evidence-based family interventions for 
this population are needed, as are similar studies in other subtypes of pediatric cancer.   
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